Companies ask FDA for regulation, improvement of data collection from digital health devices
The FDA should consider regulating how data gathered from digital health devices like continuous glucose monitors and sensors are incorporated into clinical-trial submissions, according to several comment letters from multiple advocate and industry organizations.
At least five organizations have submitted public comments on the FDA’s proposal examining how best to use digital health technologies (DHTs) in drug and biologic development, particularly in decentralized clinical trials.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters